Veradermics reports positive late-stage results for oral hair-loss pill VDPHL01

Veradermics announced that its experimental oral medication VDPHL01 met its primary goals in a Phase 3 trial for male pattern hair loss.

Over six months, participants taking the drug once or twice daily grew an average of 30 to 33 additional hairs per square centimeter, compared with about seven extra hairs in the placebo group.

Between 79% and 86% of treated men reported visible improvement, and investigators judged the outcomes favorable in 72% to 84% of cases, a result that pleased CEO Reid Waldman, a dermatologist.